Ayala Pharmaceuticals
Shmuel Tuvia, Ph.D., is a senior biopharmaceutical executive who began his career in drug development in the 1990s. Shmuel previously served as Chief Development Officer at Ukko, a company that is focused on developing immunotherapies for food allergies. Prior to Ukko, Shmuel held a Chief Operations Officer role at Eloxx, where he developed a clinical candidate molecule, ELX-02 for the treatment of several genetic diseases such as Cystic Fibrosis and Rett Syndrome. He also served at Chiasma Pharmaceuticals Ltd. – which has since been acquired by Amryt Pharma Plc. (NASDQA: AMYT) – as Vice President of Preclinical Research where he headed preclinical development and pharmacology of oral octreotide through the NDA submission.
Shmuel earned his MSc and BSc degrees in biology from Tel-Aviv University, Israel, and his Ph.D. with Distinction at the Sackler School of Medicine.
This person is not in any teams
This person is not in any offices
Ayala Pharmaceuticals
Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.